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Abstract 
Introduction: Formamidines pesticides have been described to induce permanent effects on development of monoaminergic 
neurotransmitter systems. The mechanisms that induce these effects are not known but it has been suggested that these effects 
could be related to monoamino oxidase (MAO) inhibition. Chlordimeform is a formamidine pesticide, which is a very weak inhibitor 
of MAO although it has been described to induce permanent and sex dependent alterations of serotoninergic system. 
Objectives and methods: In order to confirm that formamidines induce permanent alterations of monoaminergic neurotransmitter 
systems regardless of MAO inhibition, the effects of maternal exposure to chlordimeform (5 mg/kg bw, orally) on brain region dopa-
mine and noradrenaline levels of male and female offspring rats at 60 days of age were evaluated. The results showed that chlordi-
meform induced a significant decrease of noradrenaline and dopamine levels in the prefrontal cortex and striatum and of dopamine 
levels in the hippocampus, showing an interaction by sex for these regions. 
Results: Chlordimeform also caused a decrease of DOPAC levels in the striatum and of MHPG and HVA metabolites levels in the 
prefrontal cortex and striatum. Moreover, it induced an increase in the content of metabolites DOPAC and HVA in the hippocampus 
and an increase in the metabolite content of DOPAC in the striatum. Lastly, it increased the turnover of DA in the hippocampus and 
striatum and decreased the turnover of NA and DA in frontal cortex, as well as the NA in striatum. 
Conclusions: The present findings indicate that maternal exposure to chlordimeform altered dopaminergic and noradrenergic neu-
rochemistry in their offspring in a region and sex dependent way, and those variations confirm that other mechanisms different from 
MAO inhibition are implicated.
Keywords: Chlordimeform; formamidines; neurodevelopmental toxicity; dopamine; noradrenaline; rats; human risk assessment
Resumen
Introducción: Se ha descrito que los pesticidas formamidínicos inducen efectos permanentes en el desarrollo de los sistemas de 
neurotransmisores monoaminérgicos. Los mecanismos por los que se inducen estos efectos no se conocen, pero se ha sugerido 
que podrían estar relacionados con la inhibición de la monoamino oxidasa (MAO). El clordimeformo, es un pesticida formamidínico, 
del que se han descrito que induce una alteración permanente del sistema serotoninérgico región y sexo dependiente, aunque es 
un inhibidor muy débil de la MAO. 
Objetivos y métodos: Con el objetivo de confirmar que las formamidinas produce alteraciones permanentes de los neurotransmi-
sores monoaminérgicos independientemente de la inhibición de la MAO, se evaluaron los efectos sobre los niveles de dopamina y 
serotonina en regiones cerebrales de ratas macho y hembra a los 60 días de edad tras la exposición maternal al clordimeformo (5 
mg/kg de peso corporal). 
Resultados: El clordimeformo indujo una disminución significativa de los niveles de noradrenalina y dopamina en las regiones ce-
rebrales corteza frontal, cuerpo estriado, así como de la dopamina en el hipocampo mostrando una interacción por sexo en esta 
regiones. El clordimeformo además, originó un descenso de los metabolitos MHPG y HVA en corteza frontal y cuerpo estriado y del 
metabolito DOPAC en el cuerpo estriado. También, indujo un aumento en el contenido de los metabolitos DOPAC y HVA en hipocam-
po y un aumento del contenido de DOPAC en el cuerpo estriado. Por ultimo aumentó la tasa de recambio de DA en el hipocampo y 
cuerpo estriado y disminuyó la tasa de recambio de la NA y DA en corteza frontal y así como de la NA en cuerpo estriado. 
Conclusiones: Los presentes resultados indican que las formamidinas y en particular el clordimeformo, inducen, tras la exposición 
maternal, una alteración permanente de los sistemas dopaminérgico y noradrenérgico de forma región y sexo dependiente en la 
descendencia, lo cual confina que estas alteraciones se deben a mecanismos distintos de la inhibición de la MAO.
Palabras clave: Clordimeformo, formamidinas, neurotoxicidad en el desarrollo, dopamina, noradrenalina, ratas, evaluación del riesgo para el hombre
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Introduction 
Pesticides pose a growing risk to health, with a specific 
concern about the possible permanent effects that the-
se compounds may have on the development of orga-
nisms. Formamidine pesticides has been reported to in-
duce permanent alteration of brain development. In this 
regard, it has been described for the formamidine com-
pound amitraz, the induction of permanent alterations on 
the development of central nervous system (CNS) such as 
those that affect monoamine neurotransmitter systems1. 
Moreover, chlordimeform [N2-(4-chloro-o-tolyl)-N1.N1-di-
methylformamidine] (Figure 1), which is another member 
of formamidines family, it has been also reported that in-
duce permanent alterations of serotoninergic system2. The 
mechanism by which these effects occur is not known. 
On the other hand, monoamine oxidase (MAO) inhibition 
was among the first biochemical actions of the formami-
dines that were reported3-4. Thus, aminergic mechanism 
of action of chlordimeform was quickly postulated and 
adopted because neuronal MAO participates in metabo-
lic inactivation of biogenic monoamines which include the 
neurotransmitters serotonin, norepinephrine, and dopami-
ne. In addition, chlordimeform is an antagonist of reserpine 
effects5, alters prostaglandin synthesis6, has α2 receptor 
agonist properties7, and is an endocrine disruptor8. 
Currently it is assumed that the monoaminergic neuro-
transmitters play a role during development, defined as 
“morphogenetic”9-12. Any change in the levels of catecho-
lamines during development could have a profound effect 
on brain development, both structural and functional13. In 
this sense, it has been suggested as a possible mecha-
nism of action the inhibition of MAO which may alter the 
levels of monoaminergic neurotransmitters, although other 
mechanisms as endocrine disruption on sex hormones 
that control the expression of enzymes that catalyze the 
synthesis and metabolism of the monoamine neurotrans-
mitters cannot be excluded2. 
According to all exposed above, we performed a study 
to establish if maternal exposure to formamidines during 
gestation and lactation induces permanent alterations on 
dopaminergic and noradrenergic systems in adult age. 
Chlordimeform was chosen because it is the most repre-
sentative compound in its group which presents a very 
low inhibition of MAO, allowing us to study more clearly 
whether the permanent changes observed on levels of 
these neurotransmitters are due to an alteration of the en-
zymes that catalyze the synthesis and metabolism of the-
se neurotransmitter rather than inhibition of MAO.
This work focuses its interest in providing new data of for-
mamidines induced neurotoxicity during nervous system 
development, because new compounds of this family are 
being developed with therapeutic applications for which 
these effects are not considered in their risk assessment, 
which poses a potential health hazard.
Materials and methods 
Biological material 
All experiments were performed in accordance with Eu-
ropean Union guidelines (2003/65/CE) and Spanish re-
gulations (BOE 67/8509-12, 1988) regarding the use of 
laboratory animals. Six pregnant Wistar rats were housed 
individually in polycarbonate cages and were assigned 
randomly to two experimental groups: a chlordimeform 
treatment group (n = 3) and a control group (n = 3).
Test Chemical and Treatment
Chlordimeform (Sigma, Madrid, Spain) was dissolved in 
corn oil to provide fast and complete absorption and was 
administered orally by gavage in a volume of 2 mg/ml. 
The animals received daily chlordimeform at the dose of 
5 mg/kg on days 6 to 21 of pregnancy (GD 6-21) and 
on days 1 to 10 of lactation (PN 1-10). Control dams 
received vehicle (corn oil 2.5 ml/kg) on the same sche-
dules. Dose of chlordimeform was selected based on a 
previous preliminary study that indicated this dose was 
the higher one that did not cause weight loss or morta-
lity, any reduction of food or water intake as well as did 
not induce haematological modifications of other clinical 
histopathological signs of overt toxicity. Moreover we did 
not see any changes in suckling of maternal caretaking. 
None of the prenatal or postnatal treatment evoked a sig-
nificant change in weight of any of the brain regions on 
PN 60 (data not shown).
Dams were examined daily throughout the gestation and 
lactation periods for mortality, general appearance and 
behavior. The maternal body weights were measured on 
GD 1, GD 5, GD 6, GD 15 and GD 20. Food and water 
consumption during pregnancy, length of gestation, litter 
size and sex ratio were also assessed. 
On PN1, all litters were examined externally, sexed and 
weighed. Litters were organized in groups of twelve pups, 
six males and six females. Litters were weighed at PN 
1, PN 7, PN14 and PN 21. The offspring were weaned 
on lactation day 21 and were maintained in appropriate 
conditions, housed individually and without any treatment 
with full access to food and water until adult age. The stu-
dy was organized in treated groups of six males and six 
females randomly selected respectively from the dams’ 
Figure 1: Chlodimeform chemical structure (C10H13Cl N2).
Cl N= CH - N
CH3
CH3
CH3
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litters exposed to chlordimeform, and control groups of 
six males and six female’s pups randomly selected res-
pectively from the control dams’ litters.
At PN 60, male and female rats from control and treated 
groups (pups from control dams, and pups from dams 
exposed to chlordimeform, respectively) were sacrificed 
by decapitation. The brain was removed quickly and the 
hypothalamus, midbrain, medulla oblongata, cerebellum, 
brainstem, hippocampus, striatum and prefrontal cortex 
were rapidly dissected out at 4ºC14. Tissues were rapidly 
weighed and stored at -80 ºC until analysis. All data were 
collected by experimenters blind to the treatment condi-
tion of the offspring.
Determination of monoamine levels
Following sample collections, 300-800 μl of 0.4 M HClO4 
containing 0.1% (w/v) Na2S2O5 was added to the tissues, 
and the mixture was homogenized by sonication before 
neurochemical evaluation was performed. The homo-
genates were centrifuged for 15 min at 20000 g at 4ºC 
and aliquots of supernatants were taken for analysis of 
norepinephrine (NE), dopamine (DA) and its metabolites 
[3,4-hydroxyphenylacetic acid (DOPAC) and homovanillic 
acid (HVA)] using a high performance liquid chromatogra-
phy (HPLC) technique with electrochemical detection15,2. 
Also, aliquots of supernatants were taken for analysis of 
the norepinephrine metabolite [3-metoxy-4-hydroxyphen-
ylethyleneglycol (MHPG)] by HPLC with fluorimetric detec-
tion16,2. Volumes of 200-300 μl of the supernatants (in 0.4 
M HClO4) were treated for 3 min at 100 ºC in a water bath. 
The samples were then cooled and 30-45 μl of 2 M NaOH 
were added (final pH: ca. 1.5) and aliquots were injected 
into a reversed phase HPLC system. For the analysis of 
the catecholamines NA, DA, DOPAC and HVA, the mobile 
phase consisted of 0.1 M Na2HPO4.2H2O, 0.1 M citric 
acid (pH 3.5), 1.6 mM octane sulphonic acid, 0.9 mM 
EDTA and 10% (v/v) methanol. Elution was performed at a 
flow rate of 1 ml/min and the working electrode potential 
was set at 0.85 V for catecholamines. For the analysis of 
the norepinephrine metabolite (MHPG), the mobile phase 
consisted of 0.06 M Na2HPO4.2H2O, 0.03 M citric acid 
and 6% (v/v) methanol. Elution was performed at a flow 
rate of 1.5 ml/min. Excitation and emission wavelengths of 
the detector were 275 and 315 nm, respectively.
Peak areas in the sample chromatograms were quantita-
ted by external standard technique using solutions of the 
catecholamines (NE, DA, DOPAC and HVA), and norepi-
nephrine metabolite (MPHG). DA and NA turnover was 
calculated as ratio of metabolite to neurotransmitter.
Data analysis
Statistical analysis of data was performed using a Statgra-
phics software, version Plus 4.1 for windows. Values are 
expressed as mean ± S.E.M. obtained from 12 animals, 
six males and six females, in each group (control and trea-
ted groups). For values combined for males and females, 
a two-way ANOVA with treatment × sex interaction was the 
initial test used. Where a significant treatment × sex interac-
tion was detected, a separate Student’s t test was carried 
out for each sex. The results were considered significant at 
P<0.05. Results significantly different from controls are also 
presented as change from control (%).
Results 
Maternal and offspring body weight, physical and general 
activity development were unaffected by the exposure of 
dams to chlordimeform (5 mg/kg bw orally on days 6 to 
21 of pregnancy and 1 to 10 of lactation). 
Brain tissues levels of dopamine, noradrenaline, its meta-
bolite and the turnover in rat pups at PN 60 are presented 
in Tables IA and IIA. In the hypothalamus, midbrain, ce-
rebellum, medulla oblongata and brainstem the levels of 
DA, NA, DOPAC, HVA and MHPG, and the DA and NA 
turnover were not modified by dam exposure to chlordi-
meform in males and females rat pups at PN 60. In male 
and female offspring, chlordimeform induced a significant 
decrease of noradrenaline and dopamine content in the 
prefrontal cortex and striatum and of dopamine content 
in the hippocampus compared to control animals (Ta-
bles IB and IIB). Chlordimeform also caused a decrease 
in the metabolites levels of DOPAC in the striatum and 
MHPG and HVA in the prefrontal cortex and striatum in 
males and females offspring (Tables IB and IIB). Moreo-
ver, it induced an increase in the content of metabolites 
DOPAC and HVA in the hippocampus and an increase in 
the metabolite content of DOPAC in the striatum in ma-
les and females offspring (Tables IB and IIB). Lastly, it 
increased the turnover rate of DA in the hippocampus 
and striatum and decreased the turnover rate of NA and 
DA in frontal cortex, as well as the NA in striatum in males 
and females offspring (Tables IB and IIB). Chlordime-
form displayed in the striatum for dopamine content, in 
the prefrontal cortex and hippocampus for dopamine, its 
metabolites and turnover, and in the striatum and prefron-
tal cortex for noradrenaline, its metabolite and turnover a 
significant sex interaction with the treatment effect (Ta-
bles IB and IIB).
Discussion 
The present study shows that prenatal and postnatal ex-
posure to chlordimeform (5 mg/kg bw orally on days 6 to 
21 of pregnancy and 1 to 10 of lactation) was not able to 
induce maternal toxicity since during pregnancy maternal 
weight gain of treated rats was not modified. However, 
chlordimeform administered during pregnancy and lacta-
tion leads to permanent alterations of the dopaminergic 
and noradrenergic systems in a sex and region depen-
dent way at 60 days of age in rats. Chlordimeform affec-
ted the content of DA and NA only in the regions frontal
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cortex, hippocampus and striatum displaying a sex inte-
raction with the treatment effect. The effects observed in 
our study included a significant decrease of noradrena-
line and dopamine contents in the prefrontal cortex and 
striatum and of dopamine content in the hippocampus of 
male and female offspring. Chlordimeform also caused a 
decrease of DOPAC levels in the striatum and of MHPG 
and HVA metabolites levels in the prefrontal cortex and 
striatum, although it induced an increase in the content 
of metabolites DOPAC and HVA in the hippocampus and 
an increase in the metabolite content of DOPAC in the 
striatum of male and female offspring. Lastly, it increased 
the turnover of DA in the hippocampus and striatum and 
decreased the turnover of NA and DA in frontal cortex, as 
well as the NA in striatum of male and female offspring.
Developmental neurotoxicity involves alterations in beha-
vior, neurohistology, neurochemistry and/or gross dys-
morphology of central nervous system occurring in the 
offspring, as a result of chemical exposure of the mother 
during pregnancy or lactation. The mechanism through 
which these permanent effects on monoaminergic sys-
tems take place is unknown, but monoamine neurotrans-
mitters, such as 5-HT, DA and NA regulate brain deve-
HT: hypothalamus; MB: midbrain; CB: cerebellum; MO: medulla oblongata; BS: brainstem; PFC: prefrontal cortex; ST: striatum; HC: hippocampus. 
Data represent means ± S.E.M. with values for males and females combined (n=12: 6 males + 6 females). 
Statistical significance is reported for the *P<0.05, **P<0.01 and ***P<0.001 levels compared with the control group.
a Percentage change from control values.
b Significant treatment × sex interaction.
PFC: prefrontal cortex. Other tissue values were not evaluated because of the lack of treatment × sex interactions.
Values are mean ± S.E.M.; control animals (n= 6 males, n= 6 females); treated group (n= 6 males, n= 6 females).
Statistical significance is reported for the **P<0.01 and ***P<0.001 levels compared with the control group within each sex as determined by one-way ANOVA, 
followed by the Student´s t test.
a Percentage change from control values.
Table IA: PFC: prefrontal cortex. Other tissue values were not evaluated because of the lack of treatment × sex interactions.
Values are mean ± S.E.M.; control animals (n= 6 males, n= 6 females); treated group (n= 6 males, n= 6 females).
Statistical significance is reported for the **P<0.01 and ***P<0.001 levels compared with the control group within each sex as determined by one-way ANOVA, followed 
by the Student´s t test.
a Percentage change from control values.
Table IB: Statistical analysis for tissue values with significant treatment × sex interaction.
 DA (ng/g) DOPAC (ng/g) HVA (ng/g) (DOPAC+HVA)/DA
 Control Treated group Control Treated group Control Treated group Control Treated group
 group (pups from group (pups from group (pups from group (pups from
  treated dams)  treated dams)  treated dams)  treated dams)
HT 1296,34 ± 8,02 1306,23 ± 10,47 110,24 ± 1,71 111,28 ± 3,13 37,67 ± 0,89 37,92 ± 1,18 0,11 ± 0,00 0,1 ± 0,00
MB 1262,29 ± 27,37 1276,79 ± 26,49 60,22 ± 1,31 60,84 ± 0,84 34,00 ± 0,92 34,33 ± 1,09 0,07 ± 0,00 0,07 ± 0,00
CB 91,86 ± 0,69 92,34 ± 0,84 22,18 ± 0,38 22,22 ± 0,49 11,22 ± 0,30 11,24 ± 0,27 0,36 ± 0,01 0,36 ± 0,00
MO 304,44 ± 2,47 306,42 ± 4,52 21,19 ± 0,30 21,32 ± 0,32 11,03 ± 0,23 11,08 ± 0,22 0,11 ± 0,00 0,11 ± 0,00
BS 464,55 ± 4,26 469,47 ± 2,81 10,88 ± 0,26 10,94 ± 0,31 9,67 ± 0,08 9,73 ± 0,14 0,04 ± 0,00 0,04 ± 0,00
PFC 495,56 ± 5,25 b378,02 ± 22,96 46,03 ± 0,43 b33,54 ± 1,74 31,25 ± 1,39 b22,52 ± 0,29 0,16 ± 0,00 b0,15 ± 0,00
ST 7234,48 ± 23,25 b6337,99 ± 43,89 821,85 ± 8,19 1118,99 ± 8,16***, 550,04 ± 4,49 456,62 ± 4,38***, 0,19 ± 0,00 0,25 ± 0,00***,
    a (36,15%)  a (-16,98%)  a (31,12%)
HC 514,42 ± 13,75 b412,91± 28,34 9,55 ± 0,18 b11,68 ± 0,41 4,69 ± 0,08 b7,55 ± 0,40 0,03 ± 0,00 b0,05 ± 0,00
Tissue
 DA (ng/g) DOPAC (ng/g) HVA (ng/g) (DOPAC+HVA)/DA
  Control Treated group Control Treated group Control Treated group Control Treated group
  group (pups from group (pups from group (pups from group (pups from
   treated dams)  treated dams)  treated dams)  treated dams)
  504,63  431,46 46,01 37,58 28,17 22,83 0,15 0,14
 Males ± 3,24   ± 2,45***,  ± 0,47 ± 0,31***, ± 0,23  ± 0,32***, ± 0,001 ± 0,001***,
    a (-14,50%)  a (-18,33%)  a (-18,98%)  a (-4,77%)
  486,49 324,59 46,05 29,51 34,32 22,21 0,17 0,16
 Females ± 4,14 ± 3,43***, ± 0,44 ± 0,22***, ± 0,63 ± 0,20***, ± 0,00 ± 0,00*,
    a (-33,28%)  a (-35,92%)  a (-35,28%)   a (-3,53%)
  7197,85 6237,08
 Males ± 18,59 ± 11,46***, – – – – – –
     a (-13,35%)
  7271,10 6438,90 
 Females ± 17,51 ± 5,82***, – – – – – –
    a (-11,45%)
  483,85 347,08 9,82 10,89 4,79 8,47 0,03 0,06 
 Males ± 3,20 ± 4,26***, ± 0,08 ± 0,13***, ± 0,09 ± 0,10***, ± 0,00 ± 0,00*,
    a (-28,27%)  a (10,88%)  a (76,92%)  a (84,76%)
  545,00 478,73 9,28 12,47 4,59 6,64 0,03 0,04
  ± 5,63 ± 3,91***, ± 0,19 ± 0,32***, ± 0,06 ± 0,10***, ± 0,00 ± 0,00***,
    a (-12,16%)  a (34,32%)  a (44,55%)  a (56,72%)
Tissue
PFC
ST
HC
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lopment prior to assuming their roles as transmitters in 
the mature brain17-19, thus any circumstance that affects 
these neurotransmitters in the developing brain can alter 
the final structure and function of that brain. Since the 
endogenous levels of DA and NA are highly regulated by 
MAO, any change in this enzyme can profoundly affect 
the developing brain. In this regard, it has been repor-
ted that gestational exposure to MAO inhibitors clorgyline 
and deprenyl produces in offspring at 30 days of age, a 
significant reduction of serotonergic innervation particu-
larly in the cerebral cortex20, but not in the dopaminergic 
and noradrenergic innervation which suggests that besi-
des MAO inhibition other mechanism should be implica-
ted in the alteration observed. On the other hand, ami-
traz, which is a potent MAO inhibitor3, has been shown 
to induce permanent alterations of monominergic neuro-
transmitter systems2 similar to those induced by chlor-
dimeform through gestational and lactational exposure. 
However, chlordimeform is a very week inhibitor of MAO, 
but presents similar permanent regional and sexual de-
pendent effects which suggest that MAO inhibition could 
not support the alterations in dopaminergic and serotoni-
nergic systems observed in the present study, and thus 
in formamidine pesticides, confirming that other mecha-
nisms are implicated. 
On the other hand, it has been also described that ste-
roids play a role in the development of catecholamine 
systems21-24, and may play a critical role in mammalian 
brain developmental of both sexes25. In this sense chlor-
dimeform has been reported to disruptor different ste-
roids hormones8, which could also contribute to the 
permanent effects observed. Moreover, chlordimeform 
could also affect the neuronal cell replication, differen-
tiation, synaptogenesis and axonogenesis, steroid me-
tabolism and functional development of neurotransmitter 
systems, effects that could result in behavioral alterations 
observed in previous studies after developmental expo-
sure to chlordimeform26. The loss of dopaminergic and 
noradrenergic projections could also play an important 
PFC: prefrontal cortex. Other tissue values were not evaluated because of the lack of treatment × sex interactions.
Values are mean ± S.E.M.; control animals (n= 6 males, n= 6 females); treated group (n= 6 males, n= 6 females).
Statistical significance is reported for the **P<0.01 and ***P<0.001 levels compared with the control group within each sex as determined by one-way ANOVA, 
followed by the Student´s t test.
a Percentage change from control values.
Table IIB: Statistical analysis for tissue values with significant treatment × sex interaction
 NA (ng/g) MHPG (ng/g) MHPG/NA
 Control Treated group Control Treated group Control Treated group
 group (pups from group (pups from group (pups from
  treated dams)  treated dams)  treated dams)
 243,71  196,29 ± 1,05***,  52,43 41,13 ± 0,16***, 0,22 0,21 ± 0,001*,
 ± 1,15 a (-19,46%) ± 0,33 a (-21,55%) ± 0,001 a (-2,59%)
 225,04 165,25 ± 0,95***, 53,05 34,15 ± 0,33***, 0,24 0,21 ± 0,003***,
 ± 0,60 a (-26,57%) ± 0,54 a (-35,63%) ± 0,003 a (-12,33%)
 173,40 154,01 ± 0,80***, 81,98 68,21 ± 0,60***,    0,47 0,44± 0,00**,
 ± 1,19 a (-11,18%) ± 0,68 a (-16,80%) ± 0,01 a (-6,35%)
 158,07 125,59 ± 0,39***, 80,04 51,18 ± 0,34***, 0,51 0,41 ± 0,00***,
 ± 1,71 a (-20,54%) ± 0,40 a (-36,06%) ± 0,01 a (-19,58%)
Tissue
Males
PFC
ST
Males
Females
Females
HT: hypothalamus; MB: midbrain; CB: cerebellum; MO: medulla oblongata; BS: brainstem; PFC: prefrontal cortex; ST: striatum; HC: hippocampus. 
Data represent means ± S.E.M. with values for males and females combined (n=12: 6 males + 6 females). 
Statistical significance is reported for the *P<0.05, **P<0.01 and ***P<0.001 levels compared with the control group.
a Percentage change from control values.
b Significant treatment × sex interaction.
Table IIA: Tissue NA and MHPGconcentrations in male and female rat pups observed at 60 days of age after the exposure of dams to chlordimeform (5 mg/kg bw orally 
on days 6 to 21 of pregnancy and 1 to 10 of lactation).
 NA (ng/g) MHPG (ng/g) MHPG/NA
 Control Treated group Control Treated group Control Treated group
 group (pups from group (pups from group (pups from
  treated dams)  treated dams)  treated dams)
HT 1338,98 ± 10,80 1355,06 ± 17,17 48,47± 0,75 49,06 ± 0,79 0,04 ± 0,00 0,04 ± 0,00
MB 579,97± 15,72 587,54± 20,84 45,00± 0,67 45,50± 0,62 0,08± 0,00 0,08± 0,00
CB 232,96± 3,39 235,09± 5,97 24,40± 0,55 24,54± 0,57 0,10± 0,00 0,10± 0,00
MO 244,22± 2,77 244,00± 3,98 28,45± 0,25 28,67± 0,39 0,12± 0,00 0,12± 0,00
BS 420,66± 8,99 426,74± 7,01 23,51± 0,33 23,84± 0,43 0,06± 0,00 0,06± 0,00
PFC 234,37± 4,08 b180,77± 6,69 52,74± 0,45 b37,64± 1,51 0,23± 0,00 b0,21± 0,00
ST 165,73± 3,56 b139,80± 6,09 81,01± 0,68 b59,69± 3,66 0,49± 0,01 b0,43± 0,01
HC 242,26± 7,86 245,86± 9,21 34,78± 0,30 35,04± 0,30 0,14± 0,00 0,14± 0,01
Tissue
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role in the behavioral alterations. Prenatal exposure to 
chlordimeform may result in either direct damage or en-
hanced vulnerability of the neurotransmitter systems to 
future toxic insult. 
Given that the dopamine and noradrenaline systems 
alterations in the brain regions of our study, as well as 
the serotonin system alteration from our previous study2 
with chlordimeform (frontal cortex, striatum, and hippo-
campus) was the same as those affected by amitraz1 it 
can be inferred that the mechanism by which formami-
dines alter CNS development is similar. Moreover, these 
brain regions participate in the regulation of learning and 
memory processes27-32, thus, it could be considered that 
these processes could be compromised by exposure 
during gestation and lactation to formamidines. In addi-
tion, the dysfunction in serotonin and dopamine systems 
are involved in appetite, affective, neuropsychiatric disor-
ders33-36, among others, which could be also induced by 
formamidine exposure during development. Further stu-
dies are needed to test these functions to confirm that 
alteration of these neurotransmitter systems is the cause 
of some of these dysfunctions. 
Conclusion 
The results of present work show that formamidines, 
particularly chlordimeform, cause developmental neuro-
toxicity at monoaminergic neurotransmitter systems le-
vel and confirm that other mechanism aside from MAO 
inhibition is implicated. Further studies are required to 
determine the possible mechanisms through which for-
mamidines induced these effects, specifically the hor-
monal disruption effects. a pathologic examination in the 
affected regions to determine the effect on the number 
of neurons is also needed, to determine if there is a re-
duction in innervation. Prenatal exposure to formamidine 
may result in either direct damage to or enhanced vul-
nerability of the neurotransmitter systems to future toxic 
insult. Due to the fact that monoaminergic neurotrans-
mitters dysfunctions are related with appetite, affective, 
neurological and psychiatric disorders, behavioral studies 
of formamidines are also needed to clarify the outcomes 
of long-term alterations in these monoaminergic neu-
rotransmitters systems. Currently, new molecules with 
therapeutic application are being developed as N-hydro-
xy-N-(4-butyl-2-methylphenyl) formamidine (HET0016) 
with protective effects against cardiovascular and cere-
brovascular diseases. Until now the risk assessment of 
the family of these compounds has been taken from the 
standpoint of carcinogenesis. In view of these results and 
our previous results it might be appropriate to reconsider 
the risk assessment of the members of this family based 
not only on their possible carcinogenic effects but also in 
the neurotoxic effects during development. The results 
reported in this study are of great importance and should 
be incorporated into the risk assessment of pesticides 
formamidines group.
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